HC Wainwright Estimates Cytokinetics Q1 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Cytokinetics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($1.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.61) EPS and Q4 2026 earnings at ($1.89) EPS.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.26) earnings per share.

Several other research analysts have also weighed in on CYTK. Citizens Jmp upped their target price on shares of Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Morgan Stanley set a $90.00 price target on Cytokinetics in a research note on Thursday, January 8th. Truist Financial upped their price target on Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. Barclays initiated coverage on Cytokinetics in a report on Wednesday, January 28th. They set an “overweight” rating and a $87.00 price objective for the company. Finally, Bank of America reiterated a “neutral” rating on shares of Cytokinetics in a research report on Wednesday. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Cytokinetics Stock Down 0.4%

Shares of CYTK opened at $62.63 on Thursday. Cytokinetics has a 52-week low of $29.31 and a 52-week high of $70.98. The company has a 50-day simple moving average of $64.21 and a 200-day simple moving average of $58.38. The company has a market capitalization of $7.66 billion, a PE ratio of -9.59 and a beta of 0.54.

Institutional Investors Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Cytokinetics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after buying an additional 191,336 shares during the period. State Street Corp raised its holdings in Cytokinetics by 3.7% in the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after acquiring an additional 207,961 shares during the last quarter. Deep Track Capital LP lifted its stake in shares of Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after purchasing an additional 650,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of Cytokinetics by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after purchasing an additional 15,815 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in shares of Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after purchasing an additional 384,469 shares during the last quarter.

Insider Activity at Cytokinetics

In related news, Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the sale, the director owned 32,444 shares in the company, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 28,064 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $66.72, for a total transaction of $1,872,430.08. Following the completion of the transaction, the director directly owned 9,977 shares of the company’s stock, valued at $665,665.44. The trade was a 73.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,385 shares of company stock valued at $9,817,158 in the last ninety days. 2.70% of the stock is owned by insiders.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.